ESMO-ESGO recommendations for early-stage and borderline ovarian cancer

  • Colombo N & al.
  • Ann Oncol
  • 1 May 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

This is part 1 of a 2-part series on the new ESMO-ESGO recommendations for ovarian cancer.


  • European Society for Medical Oncology (ESMO) and European Society of Gynaecologial Oncology (ESGO) issue recommendations for the management of early-stage and borderline ovarian cancer.

Key recommendations

  • Surgical management:
    • Perform laparotomy for early-stage cancer.
    • Minimally invasive surgery can be performed for restaging.
    • Peritoneal restaging surgery is mandatory.
    • Peritoneal restaging should be considered in cases of incidentally detected, apparently isolated serous tubal intraepithelial carcinoma (STIC) lesions.
    • Surgical staging with systematic lymph node dissection of the pelvic and the paraaortic regions is the standard.
  • Fertility-sparing surgery:
    • Can be offered to all stage IA and IC1 low-grade carcinomas, but not for stage >I.
  • Adjuvant chemotherapy:
    • Recommended for patients with stage I-IIA ovarian cancer.
    • Not recommended for incidentally detected isolated STIC lesions.
    • Carboplatin alone or in combination with paclitaxel is acceptable treatment regimen; ≥3 cycles are recommended.
  • Borderline ovarian tumors (BOTs):
    • Offer fertility-sparing surgery to young patients.
    • Unilateral salpingo-oophorectomy is recommended for mucinous BOTs.
    • Cystectomy may be offered for serous BOTs (sBOTs) to preserve fertility.
    • Perform peritoneal staging surgery for sBOTs.
    • Consider restaging for sBOTs with micropapillary pattern or incomplete visual exploration of the peritoneal cavity.
    • Remove peritoneal implants for staging and therapeutic purposes in sBOTs.
    • Consider fertility-sparing surgery for selected patients with stage II-III sBOTs.